These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23470864)

  • 1. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
    Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
    Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
    Kudo H; Kai H; Kajimoto H; Koga M; Takayama N; Mori T; Ikeda A; Yasuoka S; Anegawa T; Mifune H; Kato S; Hirooka Y; Imaizumi T
    Hypertension; 2009 Oct; 54(4):832-8. PubMed ID: 19704105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation.
    Kai H; Kudo H; Takayama N; Yasuoka S; Kajimoto H; Imaizumi T
    Circ J; 2009 Dec; 73(12):2198-203. PubMed ID: 19875896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.
    Takayama N; Kai H; Kudo H; Yasuoka S; Mori T; Anegawa T; Koga M; Kajimoto H; Hirooka Y; Imaizumi T
    Hypertens Res; 2011 Mar; 34(3):341-7. PubMed ID: 21124329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of aggravation of hypertensive organ damages by short-term blood pressure variability.
    Kai H; Kudo H; Takayama N; Yasuoka S; Aoki Y; Imaizumi T
    Curr Hypertens Rev; 2014; 10(3):125-33. PubMed ID: 25544288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
    Nakagaki T; Hirooka Y; Matsukawa R; Nishihara M; Nakano M; Ito K; Hoka S; Sunagawa K
    Hypertens Res; 2012 Apr; 35(4):470-6. PubMed ID: 22237482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large blood pressure variability aggravates arteriolosclerosis and cortical sclerotic changes in the kidney in hypertensive rats.
    Aoki Y; Kai H; Kajimoto H; Kudo H; Takayama N; Yasuoka S; Anegawa T; Iwamoto Y; Uchiwa H; Fukuda K; Kage M; Kato S; Fukumoto Y; Imaizumi T
    Circ J; 2014; 78(9):2284-91. PubMed ID: 24976508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
    Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
    Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.
    Downey RM; Mizuno M; Mitchell JH; Vongpatanasin W; Smith SA
    Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H788-H794. PubMed ID: 28733447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
    Tsukamoto O; Minamino T; Sanada S; Okada K; Hirata A; Fujita M; Shintani Y; Yulin L; Asano Y; Takashima S; Yamasaki S; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2006 Apr; 20(2):93-102. PubMed ID: 16761190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
    Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
    Tanabe A; Naruse M; Hara Y; Sato A; Tsuchiya K; Nishikawa T; Imaki T; Takano K
    J Hypertens; 2004 May; 22(5):1017-23. PubMed ID: 15097243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
    López-Andrés N; Martin-Fernandez B; Rossignol P; Zannad F; Lahera V; Fortuno MA; Cachofeiro V; Díez J
    Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2372-82. PubMed ID: 21926338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
    Veliotes DG; Woodiwiss AJ; Deftereos DA; Gray D; Osadchii O; Norton GR
    Hypertension; 2005 May; 45(5):914-20. PubMed ID: 15837836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.